At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Infusion of Hypertonic Saline-hetastarch in Cardiac Surgery
In Brief
A Phase 4 clinical trial evaluating Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5) for Postoperative Cardiorespiratory Failure. Completed, enrolled 50 participants across 1 site.
Detailed Summary
Cardiopulmonary bypass(CPB) is associated with increased fluid extravasation and edema formation. A continuous infusion of a mixture of hypertonic saline/hydroxyethyl starch (HSH)during CPB reduced fluid extravasation and total fluid gain during bypass in an animal model. We hypothesize that a continuous infusion of HSH will reduce fluid load and increase hemodynamic and respiratory functions in patients undergoing coronary artery bypass with CPB.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Cardiorespiratory Failure
CountriesNorway
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedMay 2007
Primary CompletionMay 2008
TodayJul 2026
First PostedMay 4, 2007
Enrollment StartApr 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.2 years ago
Interventions
Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)drug